Biomarkers

生物标志物

基本信息

批准号：
8378080
负责人：
Janine G Einspahr
金额：
$ 29.76万
依托单位：
UNIVERSITY OF ARIZONA
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/8378080
关键词：
Animal Model Apoptotic Archives Biochemical Biological Biological Assay Biological Markers Biometry Biopsy Blood Caspase Cells Chemoprevention Chemopreventive Agent Cleaved cell Clinical Trials Collaborations Collection Cutaneous Melanoma Decision Trees Development Drug Formulations Epidermis Exposure to Family Formalin Freezing Genes Genetic Transcription Goals HRAS gene Histologic Histone H2B Histones Histopathology Human Human Cell Line In Situ In Situ Nick-End Labeling Intervention Intraepithelial Neoplasia Karyometry Laboratories Laboratory Research MAP2K1 gene MAPK3 gene Measurement Measures Messenger RNA Methodology Methods Morphology Mus Neoplasm Metastasis Nuclease Protection Assays PTGS2 gene Paraffin Embedding Pathology Pathway interactions Phase Phosphoproteins Plasma Population Preclinical Testing Preparation Procedures Process Program Research Project Grants Protein Microarray Assay Protein Microchips Proteins Proteomics Quality Control Recording of previous events Research Personnel Resources Ribosomal Protein S6 Kinase Risk Sampling Services Signaling Protein Site Skin Skin Cancer Skin Carcinogenesis Slide Specimen Standardization Testing The Sun Thymine Dimers Time Tissue Microarray Tissue Sample Tissues Translational Research cancer prevention caspase 14 caspase-3 clinical application data management design filaggrin human FRAP1 protein innovation laser capture microdissection lens loricrin method development mouse model novel programs sample collection sample fixation tissue preparation tissue processing

项目摘要

The Biomarkers Core contributes to the overall program project in the; a) collection of large numbers of biologic samples in support of Projects 1, 2, and 3, b) storage and archiving of all biologic samples, c) histologic services for the sectioning of tissue blocks in support of Projects 1, 2, and 3, d) pathology review of ail tissue samples (Projects 1, 2, and 3), d) standardization of sample acquisition, fixation and/or time to freezing, and sample storage, e) distribution of samples from Projects 1, 2, and 3 to co-Investigators/collaborators, in the case of assays done off-site, f) measurement of biomarker expression in skin biopsies (Projects 1, 2, and 3), and g) measurement of agent levels in blood and periodic quality control of agents developed for clinical application in support of Core D (Project 3). We have evaluated, analyzed, and optimized assays used in the Biomarker Core and have an extensive history of measurement of analytes in both plasma and serum. In collaboration with Biometry and Data Management (Core B), the Biomarker Core has carried out the sample analyses and interacted with each Project on the transfer and/or analysis of samples, as well as on the management and interpretation of the results. Assays provided by the Core will include immunohistochemical method development and analysis, karyometric sample preparation, as well as the measurement of agent levels in skin and blood. The Core has added a proteomic methodology, Reverse Phase Protein Microarray (RPMA), a novel application for multiplexed quantitative measurement of multiple signaling proteins, many of which are phosphoproteins, from biological specimens. RPMA represents a novel means of measurement of hundreds of proteins from a single specimen. A second novel methodology in this Program Project is quantitative Nuclease Protection Assay (qNPA), a method for mRNA analysis from small tissue sections of formalin fixed paraffin embedded (FFPE) samples of selected genes arrayed onto a platform. qNPA will be a developmental aim in the Program Project and each project selected specific genes to be arrayed onto this platform including genes associated with skin cells and their transition into cancer and metastasis. This highly interactive and clinically translational research program project focuses on the successful preclinical testing of targeted chemoprevention agents in innovative mouse models (Projects 1 and 2) followed by the design and implementation of clinical trials in at risk human populations (Project 3). Detailed descriptions of the decision-tree selection process as well as the interactions between Projects and Cores are found on the Resources Format Page.

生物标志物核心为整个计划项目做出了贡献； a）收集大量生物样品，以支持项目1、2和3，b）所有生物样品的存储和归档，c）组织学服务，用于分区组织块，以支持项目1、2和3，d，d）病理学综述，对AIL组织样品的病理综述（项目1、2和3），d），d），d），d），d），d），d），dipe，dime time，dime，dime，dipe，固定，固定，固定，待定，以供待定，固定，订立，以供待遇，固定和/或时间。 freezing, and sample storage, e) distribution of samples from Projects 1, 2, and 3 to co-Investigators/collaborators, in the case of assays done off-site, f) measurement of biomarker expression in skin biopsies (Projects 1, 2, and 3), and g) measurement of agent levels in blood and periodic quality control of agents developed for clinical application in support of Core D (Project 3).我们已经评估了生物标志物核心中使用的测定，分析和优化的测定法，并具有广泛的血浆和血清分析物测量史。与生物特征和数据管理（核心B）合作，生物标志物核心进行了样本分析，并与每个项目进行了有关样本的传输和/或分析以及结果的管理和解释。核心提供的测定将包括免疫组织化学方法的开发和分析，成项测定样品制备以及皮肤和血液中药剂水平的测量。该核心添加了一种蛋白质组学方法，反相蛋白微阵列（RPMA），这是一种新型的多种信号蛋白的多重定量测量的应用，其中许多是生物标本中的磷酸蛋白。 RPMA代表了一种新颖的单个标本中数百种蛋白质的方法。该程序项目中的第二种新方法是定量的核酸酶保护测定（QNPA），一种从福尔马林固定石蜡嵌入的小组织切片（FFPE）样品的MRNA分析方法的方法，这些基因的所选基因的样品阵列驱动到平台上。 QNPA将是程序项目中的发展目标，每个项目都选择将特定基因存放到该平台上，包括与皮肤细胞相关的基因及其过渡到癌症和转移。这个高度互动和临床转化的研究计划项目重点介绍了创新小鼠模型中有针对性的化学预防剂的成功临床前测试（项目1和2），随后是在AT风险人群中设计和实施临床试验（项目3）。在资源格式页面上可以找到决策树选择过程以及项目与核心之间的交互的详细描述。